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Kimberly H Allison11, Andrew H Beck12, Christina Yau13, Jay Bowen14, Margi Sheth15, E Shelley Hwang16, Charles M Perou1,3,4,
Peter W Laird9, Li Ding6,17 and Christopher C Benz13
Recurrence rates after breast-conserving therapy may depend on genomic characteristics of cancer-adjacent, benign-appearing
tissue. Studies have not evaluated recurrence in association with multiple genomic characteristics of cancer-adjacent breast tissue.
To estimate the prevalence of DNA defects and RNA expression subtypes in cancer-adjacent, benign-appearing breast tissue at
least 2 cm from the tumor margin, cancer-adjacent, pathologically well-characterized, benign-appearing breast tissue specimens
from The Cancer Genome Atlas project were analyzed for DNA sequence, copy-number variation, DNA methylation, messenger RNA
(mRNA) sequence, and mRNA/microRNA expression. Additional samples were also analyzed by at least one of these genomic data
types and associations between genomic characteristics of normal tissue and overall survival were assessed. Approximately 40% of
cancer-adjacent, benign-appearing tissues harbored genomic defects in DNA copy number, sequence, methylation, or in RNA
sequence, although these defects did not significantly predict 10-year overall survival. Two mRNA/microRNA expression
phenotypes were observed, including an active mRNA subtype that was identified in 40% of samples. Controlling for tumor
characteristics and the presence of genomic defects, this active subtype was associated with significantly worse 10-year survival
among estrogen receptor (ER)-positive cases. This multi-platform analysis of breast cancer-adjacent samples produced genomic
findings consistent with current surgical margin guidelines, and provides evidence that extratumoral RNA expression patterns in
cancer-adjacent tissue predict overall survival among patients with ER-positive disease.
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INTRODUCTION
Local recurrence risk has been hypothesized to arise from breast
tumor multifocality and from genomic alterations in the benign-
appearing cancer-adjacent tissue. Breast tumor multifocality may
be as high as 40–60%,1,2 even for early stage (⩽ T2) disease, where
2-cm surgical margins can leave tumor foci behind in up to 42% of
cases.3 Genomic alterations in cancer-adjacent benign-appearing
tissue are also prevalent.4 A previous study demonstrated somatic
loss of heterozygosity in 6 out of 10 morphologically normal
lobules adjacent to breast cancers.5 Subsequent studies showed
shortened telomeric DNA in 450% of cases and four to five times
more prevalent loss of heterozygosity within 1 cm of microsco-
pically defined tumor margins.6 Defects can be far ranging, with
methylation differences as far as 4 cm from such margins.7 Thus,
genomic alterations in cancer-adjacent benign breast tissue may
explain local recurrence rates, which range from 6 to 20% when
breast-conserving therapy is accompanied by adjuvant therapy,8,9
but can exceed 40% when radiotherapy is not used with
breast-conserving therapy.10,11 However, these peritumor field
defects have never been significantly associated with patient survival
and recent clinical trials and surgical guidelines suggest no benefit
from wider surgical margins.12 The high prevalence of genetic and
epigenetic field defects may be mitigated by radiotherapy.
In the decades since field cancerization was first reported, the
availability of high-throughput methods for DNA and RNA
analyses have changed dramatically, allowing cancer-adjacent
tissue to be characterized more comprehensively, and avoiding
the biases inherent in utilizing only a single genomics data type.
On the basis of these methods, it is possible to identify the
prevalence of any type of genomic defect, without the biases
inherent in only utilizing a single platform. We performed RNA and
DNA analyses on breast cancer-adjacent, benign-appearing tissue,
sampled at least 2 cm from tumor margin. We then compared
sequence data for tumors and adjacent normal tissues with blood
to determine the somatic copy number and sequence changes.
Evaluating multiple data types on such matched sets of samples
allows a comprehensive picture of the genetic and epigenetic
features of cancer-adjacent, benign-appearing tissue.
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Beyond field effects, defined as defects in the genome of
histologically normal epithelium, recent work has suggested that
stromal characteristics of cancer-adjacent tissue may also affect
progression, particularly among estrogen receptor (ER)-positive
cases. Roman-Perez et al.13 showed that there were two main
expression subtypes in cancer-adjacent tissue and that one
subtype, termed active, was associated with mortality. Subsequent
research showed that this active subtype is commonly character-
ized by adipose-rich tissue,14,15 and several laboratories have
shown that adipose tissue in breast may be infiltrated by CD68-
positive immune/macrophage cells that are often arranged in
crown-like structures.16,17 Most recently, the presence of CD68-
positive cell complexes within ER-positive breast tumors was
associated with the higher risk of developing distant metastatic
disease, providing a link between these various studies.18
However, no study has examined peritumor microenvironment
effects on patient survival while also controlling for the presence
of DNA defects in the cancer-adjacent tissue.
Using multi-platform analysis of mutation, copy number,
methylation, histology, and expression data, we estimated the
prevalence of genomic defects and the expression phenotype of
cancer-adjacent normal tissues, and then evaluated these findings
in relation to overall patient survival.
RESULTS
Evidence of genomic and pathological defects in cancer-adjacent
tissue
All samples used to estimate prevalence of genomic alterations
were evaluated by a pathologist at the Biospecimen Core Resource
and a subset of 50 were re-evaluated by three pathologists who
were blinded to both genomic and clinical data. Figure 1a shows
the examples of images from frozen sections that were used to
assess the presence of tumor cells and to confirm normal histology.
Fifty samples of cancer-adjacent tissue had matching histology
images, and among these, histological re-evaluation identified only
a single sample with tumor cell foci among otherwise normal
breast tissue components. Frozen tissue sections from three other
occult tumor Inconclusive / weak evidencemissing data
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Figure 1. Multiple genomic assays demonstrate abnormalities within histologically normal, breast cancer-adjacent tissue samples. (a) Images
of frozen sections of cancer-adjacent normal tissues (TCGA-E2-A25I and TCGA-BH-A0DV). (b) Example of DNA copy-number alterations visible
in cancer-adjacent tissue (TCGA-BH-A0DZ). (c) Representative exome-sequencing comparing variant allele fraction of blood normal and
cancer-adjacent normal versus tumor (TCGA-E2-A158). (d) Representative RNA sequencing comparing variant allele fraction cancer-adjacent
normal versus tumor (TCGA-E2-A158). (e) Comparison of DNA methylation profiles between cancer-adjacent tissues and tumor tissues.
(f) Genomic alterations in samples across multiple data platforms. Adj., adjacent; TCGA, The Cancer Genome Atlas Project; VAF, variant allele
fraction.
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samples were of insufficient quality to conclusively evaluate the
presence or absence of microscopically detectable tumor cell foci.
Different DNA platforms showed variable sensitivity in identify-
ing somatic abnormalities in the cancer-adjacent tissue samples.
First, clear detectable copy-number alterations in these samples
were rare, with 10% prevalence in the triplet samples (Table 1;
Supplementary Table 3). An example of somatic DNA copy-
number alterations in tumor and adjacent normal compared with
blood from a single patient is shown in Figure 1b. Second,
sequence defects in cancer-adjacent tissue DNA were much more
common than copy-number alterations. Figure 1c shows exome-
sequence analysis, in which 25% of cancer-adjacent samples had
moderate-to-high levels of tumor-like somatic mutations (Table 1),
although the variant allele fraction was low (typically o5%),
consistent with low tumor cellularity (Supplementary Table 4). On
average, about half of a tumor’s somatically mutated loci were
expressed in matched cancer-adjacent normal tissue (sample
mean 55%, minimum 10× read depth). Only 7% of RNA-
expressed loci possessed the mutant allele detected by DNA
sequencing (Figure 1d), but 44% of specimens had at least two
detectable mutations by RNA-Seq (Table 1; Figure 1f, two or more
variant reads; Supplementary Table 4B). Finally, for DNA methyla-
tion profiles (Figure 1e), we interpreted linear methylation
patterns in the matched adjacent normal tissue as evidence of
occult tumor cells (see Materials and Methods). No statistically
significant correlation was found between median hypermethyla-
tion of 500 tumor-associated probes and tumor cellularity
(Pearson correlation P-value= 0.31, r=−0.09), suggesting that this
approach was not confounded by cellularity. We identified tumor-
like characteristics in ~ 15% of cancer-adjacent samples, whereas
another 36% of samples showed methylation abnormalities
suggestive of field cancerization (Supplementary Table 1;
Supplementary Table 5). Although extraneous sources of variation
between tumor and normal tissues (such as tissue composition
differences) and temporal changes in the tumor’s epigenetic
profile may confound such analyses, these methylation data
suggest that up to 51% of cancer-adjacent tissues possessed either
occult tumor cells or field cancerization effects.
We queried the normal tissue from 40 samples with paired
tumor, looking for significantly mutated genes from our first The
Cancer Genome Atlas project (TCGA) breast cancer manuscript.19
Thirty-one of the 40 paired tumors had mutations (n=53)
representing 17 significantly mutated genes, including 18
PIK3CA mutations and 11 TP53 mutations. Among 18 PIK3CA
mutations found in tumor, 11 were identified in the adjacent
normal, but the maximum VAF was 3.52% and 6 were under 1%.
This range of VAF values was much lower than that in tumors (from
13–60% with a median of 37% VAF). Similarly, among the 11 TP53
mutations found in tumor, 5 were present in adjacent normal, but
only 1 had VAF 41% (compared with tumor VAF range 24–84%,
median 44%).
Only one cancer-adjacent sample (BH-A0H7) showed genomic
alterations across all DNA and RNA sequence assay platforms, and
histological re-evaluation confirmed tumor cells infiltrating the
adjacent breast tissue in this sample. RNA sequence and DNA results
were not always consistent for a given sample. Among 49 samples
that had no microscopic evidence of tumor cell foci, 15 (30%) or 21
(43%) showed strong evidence of genetic or epigenetic abnormality
by at least one or two assay platforms, respectively (Figure 1f).
Expression subtypes of cancer-adjacent, benign-appearing breast
tissue
The dominant gene/microRNA expression variability among
cancer-adjacent breast tissue samples reflected inter-individual
differences in the breast microenvironment (unsupervised cluster-
ing shown in Figure 2; Supplementary Table 6). We evaluated
tumor-like messenger RNA (mRNA) expression by applying a
PAM50 tumor classifier.20 Although the majority of samples
showed normal-like gene expression (Figure 2a), 12 out of 107
showed transcript profiles similar to luminal A breast cancers
(Table 1). When we used miR data to cluster cancer-adjacent with
matched tumor samples, 5 out 102 samples showed tumor-like
miR profiles (Table 1) and clustered with tumors rather than
cancer-adjacent samples (data not shown). However, tumor-like
gene expression was not the dominant source of transcript
variation among cancer-adjacent samples. Rather, unsupervised
consensus clustering of the most variably expressed genes (3,280
Table 1. Evidence of genomic abnormalities in normal breast tissue
by data type in The Cancer Genome Atlas Project
Data type N (%)
microRNAa
Normal like 97 (95)
Tumor like 5 (5)
mRNA expressiona (microarray)
Normal like 56 (93)
Tumor like 4 (7)
mRNA expressiona (RNA-Seq)
Normal like 95 (89)
Tumor like 12 (11)
mRNA sequence (RNA-Seq)
No mutations detected 58 (56)







Evidence of tumor 4 (10)
Small evidence of tumor 8 (20)
Normal 28 (70)
Copy number pairsd
Likely evidence of tumor 6 (8)
Normal 65 (92)
DNA methylatione
Occult tumor 18 (15)
Field effect 43 (36)
Normal 57 (48)
Abbreviations: mRNA, messenger RNA; RNA-Seq, RNA sequencing; VAF,
variant allele fraction.
aFor expression-based RNA and microRNA calls, abnormal is, respectively,
defined by having a tumor-like PAM50 class and by clustering with tumor
samples.
bFor mutations from exome sequencing, high is defined as at least two
mutations and at least 50% with VAF41% in the adjacent normal,
moderate as at least 2 mutations but no 450% with VAF41%, low as at
least 2 mutations but no410% with VAF41%, and none as o2 mutations
with VAF41%.
cFor copy number triplets, evidence of tumor is defined as 4100,000 bp of
copy-number alterations shared between tumor and adjacent normal,
small evidence is defined as 1,000–99,999 bp of copy-number alterations
shared between tumor and adjacent normal.
dFor copy-number pairs, we only had tumor and adjacent normal, likely
evidence of tumor is defined as 4100,000 bp of copy-number alterations
shared between tumor and adjacent normal; however, blood normal is
needed for confirmation, which was not available.
eDNA methylation patterns were classified as reflecting occult tumor, field
cancerization, or normal as described in the Materials and Methods section.
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mRNAs) returned two stable mRNA clusters (Figure 2a), which
corresponded to the previously defined active and inactive gene
expression subtypes found in histologically normal tissue adjacent
to breast cancers.13 A two-cluster unsupervised consensus cluster-
ing solution for the most variably expressed microRNA mature
strands (303 miRs) was highly (90%) concordant with the mRNA
clusters (Figure 2b; Supplementary Figure 1). Mature strands that
were differentially abundant between the two miR-based clusters
included many that have been associated with breast cancer,
including miR-1, miR-9, miR-133a, miR-196a, and miR-200 family
members (q-valueo0.001; Figure 2c; Supplementary Table 7).
MicroRNA cluster 1 corresponded to inactive mRNA profiles, and
had high stromal and epithelial content, with lower adiposity (as
measured by histological area; Figure 2d).
Association between genomic defects, expression subtypes, and
survival
By univariate Kaplan–Meier analyses, there were no significant
associations between genetic defects (copy number, DNA
sequence, or methylation) and survival, either in all patients
(P=0.67) or among ER-positive patients (P= 0.23). However, there
was a marginal association between active/inactive expression
subtype and survival among ER-positive patients (P=0.08) (Figure 3).
Among the 76 patients with ER-positive disease, the active
subtype was significantly associated with node-negative status
(χ2-test, P= 0.02), but not with tumor subtype (χ2-test, P= 0.59),
stage (χ2-test, P= 0.93), tumor size (χ2-test, P= 0.98), or presence of
any genomic defect (Fisher’s exact test, P= 1.0). Patients with
active subtype tended to be older (average age 59.0 years) than
inactive patients (average age 54.7 years), but the difference in
age was not significant (two-sided pooled t-test, P= 0.21). Because
both previous literature and these univariate findings suggested
that microenvironment subtype may predict survival among ER-
positive (and/or hormone-treated) tumor patients, we conducted
further Cox proportional hazards (multivariable) analyses adjusting
for nodal status, intrinsic tumor subtype, tumor stage, tumor size,
patient age in decade, and presence/absence of other cancer-
adjacent genomic defects. In these multivariable analyses, active
subtype was significantly associated with poorer survival among
ER-positive cases, with a hazard ratio of 3.0 (confidence interval =
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Figure 2. Expression characteristics of cancer-adjacent tissue samples. (a) Unsupervised gene expression clustering of RNA-sequencing data
reveals two main clusters. Colored bars represent PAM50 subtype and miRNA subtype based on consensus cluster, and active/inactive subtype
from Roman-Perez et al.13 (b) Normalized abundance heatmap for the a two-cluster NMF consensus clustering solution for microRNA profiles
for 102 cancer-adjacent normals, for the 90 mature strands that had an absolute value fold change of at least 1.5 and a mean RPM of at least
25 in at least one of the two clusters. Below the heatmap, the silhouette width profile (Wcmm) calculated from the consensus membership
matrix. The covariate track shows samples scored as active versus inactive from mRNA data. (c) miRs that were differentially abundant
(FDRo0.05) between two unsupervised clusters, for the largest 25 fold changes (FC), for miRs with FC41.5 and a mean (RPM)425 in at least
one of the two clusters. (d) Association of mRNA clusters with fat, stromal, and epithelial percentages in normal tissues. FDR, false discovery
rate; NMF, non-negative matrix factorization.
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(HR 2.9), but precision was reduced (confidence interval = 0.9–9.7)
when we excluded two stage IV cases.
DISCUSSION
In this study, the prevalence of genomic alterations in cancer-
adjacent, benign-appearing breast tissue 42 cm from the tumor
margin ranged from 10% for copy-number changes to 440% for
RNA-detected mutations. The ~ 40% prevalence of detectable
genomic defects exceeds the expected prevalence of breast
cancer local/regional recurrences from clinical trial data 20 years
following breast-conserving therapy,9 but is in range of estimates
from other studies.10,11 However, in the current study, the
presence of DNA copy number, methylation, or sequence defects
was not associated with significant overall survival differences.
These observations parallel recent reports showing that isolated
tumor cells in axillary or sentinel nodes do not predict survival,
whereas microscopic detection of a larger number of nodally
infiltrated tumor cells is predictive of survival even with small
tumor foci.21 It may be that cases with low cellular burden of
unresected cancer cells do not increase recurrence rates and/or
that ablation of these isolated tumor cells by radiation therapy is
effective in preventing recurrences. Because the alterations
observed in cancer-adjacent normal mirror the defects found in
paired tumor tissue, although with a lower variant allele
frequency, we speculate that the defects represent occult tumor
cells. Previous studies have focused on the evidence of tumor cells
in the lymph nodes, the current study extends these observations
to include occult tumor cells and molecular abnormalities present
in the local peritumor microenvironment.
Our results also show that the sensitivity of any given method
to detect occult tumor cells, defined as malignant cells not
observed/observable in pathological review, can vary between
patients. DNA methylation was more sensitive in some patients
and mutations were more sensitive in others. This apparent
heterogeneity of genomic alterations among histologically
benign-appearing specimens is consistent with the heterogeneity
of defects in different subtypes of breast tumors.19 The effect of a
methylation event in one patient may mimic that of a mutation
event in another, and this molecular redundancy poses a technical
challenge for biomarker development in both tumors and in
cancer-adjacent tissue. With the advent of high-throughput
molecular methods, this challenge is becoming surmountable,
and here we used multiple genomic DNA and RNA platforms to
assess whether ‘any genomic defect’ predicts progression.
Although our data suggest that evidence of genomic defects by
itself is unlikely to influence patient survival, normal tissue RNA
expression profiles may have prognostic value.
RNA expression profiles of cancer-adjacent tissue predicted overall
survival in this data set, consistent with the previous data showing
prognostic value of RNA-based subtypes. The presence of two strong
molecular subtypes in normal breast tissue was confirmed in this
study, and it was also demonstrated that cancer-adjacent miRNA
profiles mirror those of mRNA. This tendency for microRNA and
mRNA subtypes to be correlated in normal breast contrasts with
tumor, wherein microRNA and mRNA expression data appear to
contribute distinct information or at least are non-overlapping.19 In
cancer-adjacent tissue, differential expression of miR-200, a negative
regulator of epithelial-to-mesenchymal transition, corresponds with
the inactive mRNA subtype that also shows low expression of an
epithelial-to-mesenchymal transition signature.13 Moreover, recent
findings suggest that miR-200 members may inhibit metastasis and
angiogenesis,22 consistent with observations that the inactive
subtype is associated with better survival.
Despite a small sample size with limited follow-up, the survival
analyses conducted here confirmed that expression subtypes of
the cancer-adjacent normal tissue were associated with survival
among ER-positive cases. We were unable to assess relapse as a
separate outcome because of power constraints and population
heterogeneity (stage I–IV, T1–T4). Because TCGA analyses do not
allow for subsequent molecular studies on the same specimens,
we were also unable to further investigate specific biological
mechanisms. Future work should extend the rich genomic
findings here to include more detailed characterization of micro-
environment characteristics by immunohistochemistry (IHC) or
other complementary technologies. Careful histopathological
review and re-review are important in studies of normal tissue,
particularly if normal tissue is a source of reference genomic DNA.
Further studies following cohorts of patients with distinct normal
breast tissue subtypes are needed, particularly studies with
biospecimens available for mechanistic work, complete patholo-
gical re-review (herein we had three pathologists re-review tissue
initially deemed cancer free, but emphasized 50 high priority
cases with most comprehensive genomic data), and detailed
relapse and overall survival data. Nonetheless, a growing body of
evidence suggests that extratumoral microenvironment may have
a role in progression of hormone receptor-positive disease.13,18
In summary, rich multi-platform data on histologically normal,
breast cancer-adjacent tissue provide evidence that genomically
altered cells are often present two or more centimeters from the
tumor edge. Unless altered cells are also detected microscopically,
the occult presence of such cells is unlikely to account for local
recurrence following breast-conserving therapy, considering the
high prevalence of these defects and consensus evidence that
wider surgical margins provide no clinical benefit to patients.12
However, microenvironment subtypes in cancer-adjacent tissue
may have prognostic value, and further investigation may
elucidate mechanisms by which peritumoral stroma may con-
tribute to survival.
MATERIALS AND METHODS
Cases and pathological assessment
Patients for this study provided informed consent to TCGA. Protocols were
reviewed by Institutional Review Boards at all participating institutions.





















Multivariate Cox Proportional Hazards
HR = 3.0 (CI 1.8-5.1, p=0.04)
Figure 3. Overall survival is associated with active/inactive subtype
among ER-positive patients. Kaplan–Meier curves show that patients
with active microenvironment (n= 46) have poorer survivorship
than those with inactive microenvironment (n= 30). Cox propor-
tional hazards regression was used to estimate hazard ratios,
adjusting for nodal status, intrinsic tumor subtype, tumor stage,
tumor size, patient age in decade, and presence/absence of other
cancer-adjacent genomic defects. ER, estrogen receptor; HR,
hazard ratio.
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A total of 142 cases, excised 2 cm or more away from the tumor margin
(precise distance and breast quadrant were not annotated), were analyzed
(Supplementary Table 1). All samples were reviewed by a pathologist at
TCGA’s Biospecimen Core Resource, of which 50 cases were selected for
additional detailed pathological assessment. Frozen histological sections
adjacent to sections used for molecular analyses were stained with
hemotoxylin and eosin. Hemotoxylin and eosins were scanned and digital
images were visually reviewed (K.H.A. and N.B.J.) and analyzed computa-
tionally (A.H.B). Slides were visually scored for the presence of tumor cells,
presence of benign lesions, and percent area composed of epithelium/
stroma/adipose, and a previously validated computational algorithm15 was
applied to estimate percent composition. Some samples had limited or no
visible epithelial content, and such slides were annotated ‘inconclusive’
(n=3, 6%) for evidence of tumor, but were retained in genomic analyses.
Given high correlations between visual and digital assessment, digital
estimates of percent area (epithelium/stroma/fat) were used for further
analysis. Only one sample had evidence of tumor cellularity, and three
samples (Figure 1f) were not interpretable due to poor slide quality. All
clinical, histological slides, and molecular data are available through TCGA
data portal (https://tcga-data.nci.nih.gov/tcga/) and bam files are available
at CGHub (https://cghub.ucsc.edu/).
For whole-exome sequencing, 40 cases had tumor, blood, and adjacent
normal samples for analysis. There were 40 cases with tumor, blood, and
adjacent normal samples for analysis by the single-nucleotide polymorphism
platform and an additional 71 with tumor and adjacent normal tissue but
not blood normal. The other platforms analyzed only tumor and adjacent
normal samples and include DNA methylation (n=118), mRNAseq for
mutation analysis (n=103), mRNAseq for gene expression (n=107), mRNA
by microarrays (n=60), and miRNAseq (n=102). See Supplementary Tables
1 and 2 for details. Survival analyses were conducted on 76 ER-positive cases
(46= active, 30 inactive) with mRNA expression and survival data.
Exome capture, sequencing, and alignment
All genomic data presented herein are available from TCGA Bioportal. Forty
tumor samples, and matched blood and cancer-adjacent normal samples
underwent exome capture and sequencing as previously described.19 In brief,
exome libraries were generated using customized Agilent SureSelect All
Exome v2.0 kit (Agilent Technologies, Santa Clara, CA, USA) or Nimblegen
SeqCap EZ Human Exome v2.0 (Roche, Pleasanton, CA, USA) on the Illumina
HiSeq2000 platform (Illumina, San Diego, CA, USA), and were sequenced to at
least 10 Gbp. Samples achieving 470% coverage of the ~34 Mbp consensus
coding sequence at 20× and a genotype concordance of 490% compared
with high-density SNP array data were used for mutation detection and
analysis. Somatic SNVs were identified using VarScan v2.2.623 and Soma-
ticSniper v0.7.3,24 and were filtered to remove read-mapping artifacts.23 Filter-
passed somatic mutations were annotated using NCBI/ENSEMBL; only tier 1
mutations in coding regions, splice sites, or noncoding RNA genes were
reported or validated by custom capture and deep resequencing (4150×
average depth). The validation status for somatic mutations was defined by
VarScan2, with the following parameters: minimum coverage=20; minimum
variance frequency=0.10; somatic-P-value=0.05. Somatic mutations were
measured in all three samples with ⩾ 20× coverage (Variant allele
frequency, or VAF410%), statistically significant (Fisher’s exact test;
P-valueo0.05) in the tumor, and absent (VAFo5%) in blood. Due to
alignment bias and increased false positive rate for somatic indels, only
somatic SNVs were used. Exome- and validation-sequencing experiments
were combined for final calls, yielding average sequence depth of 4300× .
mRNA expression and microRNA sequencing and expression
For mRNA, Agilent custom 244 K whole-genome microarrays were
hybridized and RNA library construction, sequencing, and analysis of
sequence data were performed as described previously.25 RNA reads were
aligned to the hg19 genome assembly using Mapsplice26 and gene
expression was quantified for the transcript models corresponding to the
TCGA GAF2.1, using RSEM27 and normalized within sample to the upper
quartile. For further details on this data processing, refer to the Description
file at the TCGA data portal under the V2_MapSpliceRSEM workflow. SNVs
detected from DNA sequencing were interrogated in cancer-adjacent tissue
RNA-sequencing using the program UNCeqR.28 SNVs with at least two reads
supporting the variant allele from DNA sequencing were defined as present
and samples with at least two variant alleles present were scored as positive.
Active/inactive mRNA subtypes were classified as described previously.13
For microRNAs, mature strand-sequencing data were generated as
described.19,29 Two normalized reads per million (RPM) data matrices for
5p and 3p mature strands were input into non-negative matrix
factorization unsupervised consensus clustering (v0.20.5, R v3.1.3):30 (a)
102 matched pairs of tumors and cancer-adjacent normal, then (b) only the
102 cancer-adjacent normal samples. For each RPM matrix, mature strands
were ranked by RPM variance, and the most variant 25% (303) strands
were clustered using the default Brunet algorithm, with 30 iterations for
each step of the rank survey across the range 2–15 clusters, and 500
iterations, respectively, for each subsequent full clustering run. For the 102
normals, we assessed two-, four-, and eight-cluster solutions via consensus
membership heatmaps, silhouette width profiles that we calculated from
the consensus membership matrices as a measure of a sample’s typical/
atypical membership status within a cluster, and concordance with mRNA
active/inactive samples; we chose the two-cluster solution for consistency
with prior knowledge about mRNA subtypes.13 Mature strands that were
differentially abundant between these clusters were identified with a two-
class unpaired SAM (samr v2.0)31 analysis in R v3.1.3, using as input the
RPM abundance matrix for the 511 mature strands with a mean RPM of at
least 1 in at least 10 of the 102 libraries, and with settings nperms= 1,000,
center.arrays = FALSE, testStatistic = ‘wilcoxon’, and fdr.output = 0.05. After
filtering differentially abundant mature strands by requiring an absolute
value fold change of at least 1.5 and a mean RPM of at least 25 in at least
one of the two clusters, we generated barplots showing the largest
positive and negative 25 fold changes. For the 90 mature strands passing
the filtering noted above, we generated A normalized abundance (row-
scaled log10(RPM+1) heatmap using pheatmap v1.0.2 (R Foundation for
Statistical Computing, Vienna, Austria).
DNA methylation profiling
DNA methylation profiling was carried out as described previously.19 In
brief, we performed bisulfite conversion on 1 μg of DNA per sample and
bisulfite-converted DNA was whole-genome amplified and enzymatically
fragmented before hybridization to BeadChip arrays (HumanMethylation27
(HM27) and HumanMethylation450 (HM450), Illumina, San Diego, CA, USA).
For HM27, mean fluorescence intensities of methylated (M) and unmethyl-
ated (U) bead types for each CpG locus were measured using Illumina
BeadArray and extracted with Illumina GenomeStudio. For HM450, the
level of DNA methylation at each CpG locus (β) was calculated as M/(M+U),
ranging from 0 to 1. Of 50 samples with pathology data, 43 samples
(HM450, n= 22; HM27, n= 21) were analyzed. We normalized data for
batch effects using ComBat.32 Extent of occult tumor, defined as malignant
cells not identified in pathological review, was assessed by regressing
cancer-adjacent methylation on corresponding tumor methylation across
500 probes hyper-methylated in breast cancer. We interpreted a linear
relationship between the two variables as suggestive of occult tumor cells.
We identified samples with altered methylation based on high slope
(40.4). Slopes with low residual s.e. (o1) were considered to have occult
tumor cells. Samples were ranked by slope and s.e. to order samples from
high to low occult tumor cell probability and to generate a heatmap. A
total of 1,000 probes with highest tumor–normal differences (500 hyper-
methylated and 500 hypo-methylated) were clustered (separately for
HM450 and HM27) using Heatplus in R/Bioconductor.
Copy number
Segmented copy-number data for tumor, blood, and cancer-adjacent
normal samples were collected as previously described.19 Forty samples
had tumor, blood, and adjacent normal samples, and another 71 had
tumor and adjacent normal tissue. Copy-number segments from cancer-
adjacent normal were compared with those of tumor and blood. To be
scored positive, a cancer-adjacent sample was required to have a segment
with at least 50% reciprocal overlap (meaning the length of overlap
between segments A and B is at least 50% of the length of A and 50% of
the length of B) with a corresponding tumor, but no overlap with
corresponding blood. Only segments with an absolute relative log2 copy-
number change 40.1 were considered. All samples that scored positive
were manually reviewed.
Survival analysis
Associations between cancer-adjacent DNA defects or gene expression
(mRNA/miRNA) subtype and overall patient survival were estimated using
Kaplan–Meier curves and multivariable Cox proportional hazards models.
Annotation of a DNA defect was defined as moderate or high for
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exome-sequencing mutation data, occult tumor contamination for methyla-
tion data, and ‘yes’ or ‘likely’ for CNV data (Supplementary Table 1).
Multivariable survival models for DNA defects were fit among all tumors and
for the subset of ER-positive tumors. Active/inactive expression subtype was
evaluated in association with survival among ER-positive tumors and was
adjusted for age (in decades: o40, 40 to o50, 50 to o60, 60 to o70, 70
+), stage (I, II, or III/IV), size (T1, T2, T3, and T4), node status (positive versus
negative), and tumor subtype (luminal A, luminal B, HER2, and basal like).
Sensitivity analyses were conducted to evaluate whether adjustment for
presence/absence of genetic defects (copy number, sequence or methyla-
tion) altered the association between extratumoral subtype and survival and
to evaluate whether exclusion of stage IV cases altered estimates of the
hazard ratio. Survival curves were censored at 10 years because few patients
had clinical follow-up data beyond this time.
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